Refractory Chronic Cough
Respiratory
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Trevi TherapeuticsNAL ER
GSKBLU-5937
Nocion Therapeutics3 mg NOC-100
Clinical Trials (3)
Total enrollment: 310 patients across 3 trials
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
Start: Nov 2023Est. completion: Jan 2025
Phase 2Completed
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Start: Dec 2020Est. completion: Nov 2021310 patients
Phase 2Completed
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
Start: Feb 2022Est. completion: Oct 2022
Phase 1Completed
Related Jobs in Respiratory
Regional Gene Therapy Consultant - Upper Midwest (IL/WI/MN)
Krystal Biotech
7m ago
$185K - $215K/yr
Regional Gene Therapy Consultant - Southwest (CO/AZ/NM/UT)
Krystal Biotech
7m ago
$185K - $215K/yr
Marketing Intern – Vertex Iberia (Spain)
Vertex Pharmaceuticals
Madrid, Spain
Yesterday
Sales Rep Neurology Region Leipzig, Halle, Gera, Jena, Weimar DE_G2M110105 - befristet bis 31.03.2027 (all genders)
Sanofi
Berlin
Yesterday
Ausbildung zum Pharmakanten (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
Yesterday
Laboratory Assistant (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
2d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space